Highlights
- Tamoxifen use in premenopausal women (aged 20-50) is associated with a 4.2-fold increased risk of endometrial cancer in per-protocol analyses.
- The risk for benign but clinically significant uterine diseases, such as endometrial polyps and hyperplasia, is elevated four- to eight-fold.
- Uterine disease risk exhibits a clear duration-dependent relationship, emphasizing the need for long-term surveillance.
- This study provides critical evidence for the Asian population, where data on young tamoxifen users was previously limited.
Background
